In summary, the present results demonstrated that the combination of fisetin with paclitaxel inhibited the migration and invasion of A549 human lung cancer cells by modulating the expression of metastasis-related genes and disrupting the structure of actin and vimentin cytoskeleton. Here, VIM is linked to lung cancer.